FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.

doi:10.1038/s41408-021-00495-3

Back to search

Article

FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.

Blood cancer journal - 27 May 2021

Daver Naval, Venugopal Sangeetha, Ravandi Farhad

Abstract excerpt

Approximately 30% of patients with newly diagnosed acute myeloid leukemia (AML) harbor mutations in the fms-like tyrosine kinase 3 (FLT3) gene. While the adverse prognostic impact of FLT3-ITDmut in AML has been clearly proven, the prognostic significance of FLT3-TKDmut remains speculative. Curren...

Topics

Aniline Compounds
Animals
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Disease Management
Drug Resistance, Neoplasm
Humans
Leukemia, Myeloid, Acute
Mutation
Protein Kinase Inhibitors
Pyrazines
Staurosporine
fms-Like Tyrosine Kinase 3

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.